RNA, U6 small nuclear 574, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-574P profile across patient tissues and cancer cell-line models. RNU6-574P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNU6-574P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNU6-574P RNA expression shows 12,813 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where RNU6-574P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-574P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-574P survival associations across molecular data types. RNU6-574P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-574P RNA expression–survival associations across cancer types. High RNU6-574P expression shows unfavorable associations in UVM, ACC, KIRC, THCA, KIRP and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNU6-574P RNA expression.
This table summarizes RNU6-574P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-574P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-574P shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, UCEC and CHOL. The KIRC box plot shows higher RNU6-574P RNA expression in normal versus tumor tissue (log2 FC = −0.500, t-test p < 0.001).
This table shows molecular features associated with RNU6-574P in patient tissues and cancer cell lines. In patient samples, RNU6-574P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
